IRS1 and ovarian carcinoma: Whereas celastrol has shown promise in the treatment of various cancers, including ovarian cancer (C. Wang et al. 2023), the potential oncogenic risks associated with the sustained activation of IRS1 should be considered (Park et al. 2024; Reiss et al. 2012).